CK2 Inhibitor or CK2B Knockdown Limits CD8+ T Cell Exhaustion and Improves the Efficacy of Anti‐PD‐1 Therapy in NSCLC In Vivo. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.